Sign In
Buy ELVN
$36.03
+0.510 (+1.44%)
At Close: Jun 03, 2026
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
04:05pm, Wednesday, 03'rd Jun 2026
Enliven will host a webcast conference call on June 11, at 8:30 a.m. ET BURLINGAME, Calif.
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.
05:25pm, Monday, 01'st Jun 2026
This oncology-focused biotech, advancing kinase inhibitors for cancer, reported a notable insider sale amid strong one-year stock gains.
Enliven Therapeutics to Present at Upcoming Investor Conferences
04:05pm, Thursday, 21'st May 2026
BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
04:46pm, Wednesday, 13'th May 2026
This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials.
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-00
Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort In patients who previously
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
04:05pm, Thursday, 07'th May 2026
Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 Strong balance sheet with $452 million in cash, cash
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million
12:26pm, Saturday, 28'th Mar 2026
Helen Louise Collins exercised and sold 40,000 Common Stock shares over March 9–10, 2026, generating proceeds of ~$1.20 million at a weighted average price of $30.07 per share. The transaction reduc
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year High – Here’s Why
01:59am, Sunday, 22'nd Mar 2026
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) hit a new 52-week high during mid-day trading on Friday. The stock traded as high as $31.76 and last traded at $30.05, with a volu
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $41.00 Consensus PT from Analysts
01:31am, Saturday, 21'st Mar 2026
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
04:05pm, Tuesday, 03'rd Mar 2026
/PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
04:05pm, Wednesday, 25'th Feb 2026
BOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of “Moderate Buy” by Brokerages
04:10am, Saturday, 21'st Feb 2026
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the stock,
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast
01:34am, Thursday, 05'th Feb 2026
Heron Therapeutics (NASDAQ: HRTX - Get Free Report) and Enliven Therapeutics (NASDAQ: ELVN - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k
12:58am, Sunday, 01'st Feb 2026
Enliven Therapeutics' Chief Scientific Officer sold 20,000 indirect shares for a total of approximately $535,100 on Jan. 20, 2026, at a weighted average price of around $26.75 per share. The sale repr
